Kodiak Sciences Inc.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases. The company specializes in next-generation therapies targeting chronic, high-prevalence ophthalmic conditions that lead to vision loss, including wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, uveitis, and macular edema secondary to inflammation. Its proprietary Antibody Biopolymer Conjugate Drug platform enables multi-modal treatments through bio-inspired antibody biopolymer conjugates. Key pipeline candidates include tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer in Phase 3 studies for retinal vascular diseases; KSI-501, a bispecific anti-IL-6 and VEGF-trap for inflammatory retinal conditions; and KSI-101, targeting IL-6 and VEGF for patients with retinal fluid and inflammation. Kodiak Sciences Inc. operates as a retina-focused biotechnology firm advancing late-stage programs to address unmet needs in ophthalmology. Founded in 2009 and headquartered in Palo Alto, California, it remains committed to developing innovative biologic medicines for complex ocular diseases.